Voyager Therapeutics (VYGR) Tops Q2 EPS by 6c

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.51), $0.06 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.85 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Medtronic completes $550 million Scientia Vascular acquisition
• Carvana (CVNA) PT Lowered to $85 at RBC Capital